Lilly sues four telehealth firms for unauthorized compounding of Mounjaro and Zepbound. 2. GLP 1 drugs remain in high demand ...

A new federal ruling means that patients will no longer have access to cheaper versions of Eli Lilly weight loss and diabetes ...

Eli Lilly (NYSE: LLY) was an unstoppable bet in the past few years, but LLY stock finally started plateauing in the latter ...

You can reach Katie on Signal at palmer.01. Amid ongoing battles over alternate supplies of blockbuster weight loss drugs, Eli Lilly filed new lawsuits against four telehealth firms and their ...

Ricks said reshoring manufacturing capacity for older essential medicines is “a valid thing,” adding that Eli Lilly is “happy to help.” ...

US President Donald Trump signed an executive order requiring drugmakers to lower prices, aligning with international rates.

Current health news covers major investments by Merck Animal Health and Gilead Sciences in the U.S., regulatory decisions ...

Eli Lilly’s stock wobbled Thursday after a looming coverage hit was detailed for its blockbuster weight-loss drug Zepbound Eli Lilly's stock wobbled Thursday after a looming coverage hit was ...

The momentum is now with Lilly. Visible Alpha, a data firm, expects its sales of obesity drugs to overtake Novo’s by 2027 ...

Global pharmaceutical shares jumped in intraday trading Monday, reversing their pre-market declines, as investors anticipated ...

INDIANAPOLIS — Eli Lilly's stock wobbled Thursday after a looming coverage hit was detailed for its blockbuster weight-loss drug Zepbound. CVS Health said the drugs Wegovy and Saxenda from rival ...

INDIANAPOLIS — Eli Lilly's stock wobbled Thursday after a looming coverage hit was detailed for its blockbuster weight-loss drug Zepbound. CVS Health said the drugs Wegovy and Saxenda from rival ...